Skip to main content
Merck10-Q: Acquisition announced

Merck to acquire Terns Pharmaceuticals for $6.7 billion to expand oncology pipeline

Source: Autobound Signal API · 95 signals tracked for Merck · updated

Get Merck's live signals in Claude or ChatGPT, or by API

AskWhat changed at Merck this week? Use Autobound signals for merck.com.

What happened

Merck entered into a definitive agreement in March 2026 to acquire clinical-stage oncology company Terns Pharmaceuticals for $53 per share, or approximately $6.7 billion.

Source

SEC EDGARMay 4, 2026

Quarterly report (Form 10-Q)

Merck 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

In March 2026, Merck entered into a definitive agreement to acquire Terns Pharmaceuticals, Inc. (Terns), a clinical-stage oncology company, for $53 per share, for a total transaction value of approximately $6.7 billion.

sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Acquisition announced

What this signalsIntegration work after a deal often opens needs for new systems and services.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
May 4, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$6.7B (acquisition of Terns Pharmaceuticals)

Details

CIK
310158
Accession number
0001628280-26-029802
Timeframe
Current quarter
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
Integration needs coming
Signal category
Strategic

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
acquisitionAnnounced

Use this data

Get every 10-Q signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/31ed8c3e-e76b-4ec5-b26c-d8434d2c63e1 returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "31ed8c3e-e76b-4ec5-b26c-d8434d2c63e1",
  "signal_type": "sec-10q",
  "signal_subtype": "acquisitionAnnounced",
  "detected_at": "2026-11-09T06:24:49.228+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "detail": "Merck entered into a definitive agreement in March 2026 to acquire clinical-stage oncology company Terns Pharmaceuticals for $53 per share, or approximately $6.7 billion. This transaction may create vendor integration and trial support opportunities as Merck advances the lead candidate TERN-701.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "acquisition of Terns Pharmaceuticals",
      "dollar_millions": 6700
    },
    "quarter": "Q1",
    "summary": "Merck to acquire Terns Pharmaceuticals for $6.7 billion to expand oncology pipeline",
    "excerpts": "In March 2026, Merck entered into a definitive agreement to acquire Terns Pharmaceuticals, Inc. (Terns), a clinical-stage oncology company, for $53 per share, for a total transaction value of approximately $6.7 billion.",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm",
    "filing_date": "2026-05-04",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "Integration needs coming",
    "signal_category": "strategic"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.